Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech
September 29, 2021 07:00 ET
|
Fortress Biotech, Inc.
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 AstraZeneca intends to advance and...
Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference
September 28, 2021 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
Fortress Biotech to Participate in Three September 2021 Investor Conferences
September 09, 2021 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights
August 16, 2021 16:01 ET
|
Fortress Biotech, Inc.
Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record Rolling NDA submission for CUTX-101 for the treatment of Menkes disease expected to begin in...
Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea
June 30, 2021 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK and SCOTTSDALE, Ariz., June 30, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today...
Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences
June 01, 2021 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
Fortress Biotech Announces Webinar Hosted by ROTH Capital Partners Featuring Partner Company Journey Medical Corporation
May 19, 2021 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK and SCOTTSDALE, Ariz., May 19, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and...
REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 17, 2021 07:00 ET
|
Fortress Biotech, Inc.
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 16, 2021 16:00 ET
|
Fortress Biotech, Inc.
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of...
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe
May 10, 2021 06:30 ET
|
Fortress Biotech, Inc.
Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney...